Outrun Therapeutics unveiled its lead program targeting HPV-positive head and neck cancer and appointed E3 ligase experts to its advisory board.
Outrun Therapeutics is a preclinical biotech company focused on protein stabilisation through E3 ligase inhibition within the cancer treatment sector
Outrun Therapeutics is a preclinical biotech company focused on protein stabilisation through E3 ligase inhibition within the cancer treatment sector. The company has developed a lead program, which is a small molecule inhibitor designed to target E3 ligase and stabilise a tumour suppressor protein in hard-to-treat solid tumors.